In August CTS begins source plasma testing as a new line of business to one of the largest plasma fractionators in the industry.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...